EDAP (MC $56 M) FDA approval for Prostate Cancer Cure in 1Q 2014 =RALLYYYYYYYYYY
A REAL LIFETIME OPPRTUNITY HERE GUYS ...
This Undiscovered Gem is brutally Underpriced and has Monster Upside Potential especially on the Upcoming FDA approval (1Q14) of Ablatherm-Hifu an very effective treatment for localized prostate cancer .
FDA approval + Low float = $12-15 within next Year . Please Do your own DD to realize the Full Potential in this Goldmine .GLTA
Market Cap: $56 Million
Cash: $10 Million
Revenue :$32 Million
Shares Out: 21,7 M
Ablatherm-HIFU a treatment for prostate cancer is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA.
Marc Oczachowski, EDAP’s chief executive officer, continued, “Therapeutic ultrasound is gradually gaining ground in cancer treatment approach. We clearly see a growing interest in minimally invasive focal therapies for cancer tumors. Our 20 years expertise in the treatment of localized prostate cancer using HIFU has long been demonstrated and we are excited to further participate in the development of such new projects aiming at improving cancer drug delivery. While we expand our expertise in HIFU to further applications, we remain fully focused on developing our HIFU technology and adapt it to the current focal therapy trend to treat prostate cancers. We believe that the focal therapy approach represents a unique opportunity for Ablatherm HIFU to become the gold standard of treatment for prostate cancer.”